| Date Filed | Type | Description |
| 10/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 7,172 shares
@ $0.6199, valued at
$4.4k
Exercised 24,474 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 3,444 shares
@ $0.6199, valued at
$2.1k
Exercised 9,956 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| Cittadine Andrew (COO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 2,624 shares
@ $0.6199, valued at
$1.6k
Exercised 8,953 restricted stock units
@ $0 |
|
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/11/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
| 07/03/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
| 07/03/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
| 07/03/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
| 07/03/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 5,104 shares
@ $0.855, valued at
$4.4k
Exercised 14,846 restricted stock units
@ $0 |
|
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/02/2023 |
SC 13G
| Klunzinger Jeffrey R. reports a 5.2% stake in Monopar Therapeutics Inc. |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/04/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 4,286 shares
@ $1.39, valued at
$6k
Exercised 13,911 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 1,842 shares
@ $1.39, valued at
$2.6k
Exercised 5,067 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| Cittadine Andrew (COO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 1,154 shares
@ $1.39, valued at
$1.6k
Exercised 4,063 restricted stock units
@ $0 |
|
| 03/27/2023 |
8-K
| Quarterly results |
|